A Study of LY2623091 in Participants With High Blood Pressure
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 304 participants.
Also called NCT02194465
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 304 participants
- Sponsor
- Registry
-
NCT02194465
-
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Canada, Puerto Rico
- Registry status
- Completed
Technical summary
Registry record NCT02194465. Randomized; double masking; primary purpose treatment. Start 2014-08 (registry gives no type); primary completion 2015-03 (actual). Results posted on 2020-06-26.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study of LY2623091 in Participants With High Blood Pressure
- Condition
- Primary Hypertension
- Intervention (Drug)
- LY2623091
- Intervention (Drug)
- Tadalafil
- Intervention (Drug)
- Spironolactone
- Intervention (Drug)
- Placebo
- Lead sponsor
- Eli Lilly and Company
Record details
- Record id
cardio:ct-nct02194465- Content hash
8c37d300d537ac772e40a5af60e4e0711ee91828aa1412ae278eaf333cade7c5